
Pioneering the treatment of common illnesses Pioneering the treatment of common illnesses

THE CHALLENGE
Now is the time Now is the time
At Vesalius, we believe it’s time to take a fresh approach to treating the diseases that drive 90 percent of human illness, and that most people worry about. Our goal is to fundamentally realign the way we view, diagnose, and treat common illnesses and we believe we can do it.
Progress in treating some of society’s most devastating illnesses has not advanced as quickly as it could because our industry has not been defining the problem correctly.
Many of the common illnesses we aim to treat – such as heart failure, high blood pressure, type II diabetes, Alzheimer’s disease, NASH, and obesity - have a single diagnosis. However, we now understand that these illnesses are not monolithic. They are a constellation of multiple genetically and biologically distinct diseases that affect patients differently.
OUR APPROACH
A new lens on common illnesses A new lens on common illnesses
Our DIAMOND™ product-platform works like a prism, enabling us to discern previously unrecognized clinical patterns in groups of patients, link these patterns to the combined effects of different genes, and identify the genetic circuits driving disease. DIAMOND creates proprietary patient-derived, cell-based experimental models to screen and characterize drug candidates to restore these circuits to healthy functioning.
Our approach combines the power of human data, advanced artificial intelligence and machine learning, genetics and genomics information, and proprietary experimental models into a uniquely potent discovery engine.
Our Team
At Vesalius Therapeutics, we believe it is time to re-think and redefine how we treat common illnesses. Founded by Flagship Pioneering, we are building a company capable of doing it.
Our Leadership
Board of Directors
Scientific Advisory Board
-
Lee Rubin
Professor of Stem Cell and Regenerative Biology, Harvard University, and Co-Director, Neuroscience Program, Harvard Stem Cell Institute
-
Paola Arlotta
Chair, Department of Stem Cell & Regenerative Biology, Harvard University
-
Percy Carter
Chief Scientific Officer, Blueprint Medicines
-
John A. Todd
Director, Wellcome Centre for Human Genetics, University of Oxford
-
Wendy Chung
Professor of Pediatrics in Medicine, Columbia University
-
Tanya Fischer
Vice President, CNS Development, Alnylam Pharmaceuticals
-
Justin Ichida
Associate Professor of Stem Cell Biology and Regenerative Medicine, University of Southern California


OPEN ROLES
Join our team Join our team
Founded by Flagship Pioneering, Vesalius is taking a new approach to tackling common, illnesses. We are patient-focused at our core. We challenge assumptions and don’t accept the status quo.
While we’re pragmatic in our approach and rigorous in our science, we’re still thinking big. Our goal is both ambitious and straight forward: to advance treatments that address some of the most significant challenges in medicine. We believe we’re well on our way.
We’re assembling a world-class team of company builders, innovators, technologists, scientists, and clinicians.
PRESS ROOM
-
08/01/2022
Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs
Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.
Read More -
03/01/2022
Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness
Flagship Pioneering today unveiled Vesalius Therapeutics, a company focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness. Flagship initially committed $75 million to support the development of Vesalius’ platform and initial pipeline of new medicines.
Read More